About Harrow Health, Inc.
https://www.harrowinc.comHarrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation.
CEO
Mark L. Baum
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-02-08 | Reverse | 1:5 |
| 2012-03-16 | Reverse | 1:8 |
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:987.54K
IWM
Weight:0.05%
Shares:775.26K
XSU.TO
Weight:0.05%
Shares:775.26K
Summary
Showing Top 3 of 123
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Ladenburg Thalmann
Buy
B. Riley Securities
Buy
BTIG
Buy
Lake Street
Buy
Craig-Hallum
Buy
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
OPALEYE MANAGEMENT INC.
Shares:3.9M
Value:$188.06M
BLACKROCK, INC.
Shares:2.55M
Value:$122.86M
BLACKROCK INC.
Shares:2.15M
Value:$103.47M
Summary
Showing Top 3 of 215
About Harrow Health, Inc.
https://www.harrowinc.comHarrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $71.64M ▲ | $39.18M ▲ | $1.02M ▼ | 1.42% ▼ | $0.03 ▼ | $11.62M ▼ |
| Q2-2025 | $63.74M ▲ | $36.1M ▼ | $5M ▲ | 7.84% ▲ | $0.14 ▲ | $15.98M ▲ |
| Q1-2025 | $47.83M ▼ | $43.54M ▲ | $-17.78M ▼ | -37.17% ▼ | $-0.5 ▼ | $-6.69M ▼ |
| Q4-2024 | $66.83M ▲ | $39.8M ▲ | $6.78M ▲ | 10.14% ▲ | $0.19 ▲ | $17.55M ▲ |
| Q3-2024 | $49.26M | $35.92M | $-4.22M | -8.57% | $-0.12 | $4.28M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $74.29M ▲ | $363.07M ▲ | $316.41M ▲ | $47.02M ▼ |
| Q2-2025 | $55.81M ▼ | $345.03M ▼ | $295.73M ▼ | $49.65M ▼ |
| Q1-2025 | $66.73M ▲ | $364.16M ▼ | $308.07M ▼ | $56.45M ▼ |
| Q4-2024 | $47.25M ▼ | $388.97M ▲ | $319.67M ▲ | $69.65M ▲ |
| Q3-2024 | $72.6M | $351.54M | $293.92M | $57.98M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.02M ▼ | $16.59M ▲ | $-225K ▲ | $4.96M ▲ | $21.33M ▲ | $16.38M ▲ |
| Q2-2025 | $5M ▲ | $-803K ▼ | $-293K ▼ | $-12.67M ▼ | $-13.76M ▼ | $-969K ▼ |
| Q1-2025 | $-17.78M ▼ | $19.67M ▲ | $-212K ▲ | $23K ▼ | $19.48M ▲ | $19.46M ▲ |
| Q4-2024 | $6.78M ▲ | $-17.78M ▼ | $-37.56M ▼ | $29.98M ▲ | $-25.35M ▼ | $-55.34M ▼ |
| Q3-2024 | $-4.22M | $2.95M | $-597K | $-721K | $1.63M | $2.35M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Other Products | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Mark L. Baum
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-02-08 | Reverse | 1:5 |
| 2012-03-16 | Reverse | 1:8 |
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:987.54K
IWM
Weight:0.05%
Shares:775.26K
XSU.TO
Weight:0.05%
Shares:775.26K
Summary
Showing Top 3 of 123
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Ladenburg Thalmann
Buy
B. Riley Securities
Buy
BTIG
Buy
Lake Street
Buy
Craig-Hallum
Buy
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
OPALEYE MANAGEMENT INC.
Shares:3.9M
Value:$188.06M
BLACKROCK, INC.
Shares:2.55M
Value:$122.86M
BLACKROCK INC.
Shares:2.15M
Value:$103.47M
Summary
Showing Top 3 of 215